// App-Quantinova.ai

5594 : Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.

Researchers

Presenter

  • Kosei Hasegawa

Principal Investigators

  • Kenji Tamura

  • Noriyuki Katsumata

  • Koji Matsumoto

  • Shunji Takahashi

  • Hirofumi Mukai

  • Hiroyuki Nomura

  • Hironobu Minami

Medical Centers

  • Saitama Medical University International Medical Center, Hidaka, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Nippon Medical School Musashikosugi Hospital, Kawasaki City, Japan

  • Hyogo Cancer Center, Hyogo, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Microsatellite instability

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved